REAGAN-UDALL FOUNDATION for the Food and Drug Administration

Automation Basics: Virtual Discussion

Wednesday, November 18, 2026 | 12 PM ET

Speaker Bios

Paul Laub
Senior Director of Automation, Genesis AEC



Paul Laub is the Senior Director of Automation at Genesis AEC, where he leads automation engineering services for biopharmaceutical and life sciences projects. With 25 years of experience, Paul specializes in distributed control systems (DCS), manufacturing execution systems (MES), and automation solutions for FDA-regulated manufacturing facilities.

Over the course of his career, Paul has led automation teams supporting projects ranging from facility expansions and process modernization efforts to new manufacturing facilities. He is passionate about building strong engineering organizations, establishing effective execution standards, and developing the next generation of automation leaders.

At Genesis AEC, Paul works closely with Process, Mechanical, Electrical, Architectural, and Construction teams to deliver practical automation solutions that support reliable operations, regulatory compliance, and successful project execution. He is a trusted advisor to both clients and company leadership and enjoys helping organizations navigate the intersection of technology, manufacturing, and project delivery.

Susan Schniepp, B.S., Chemistry
Distinguished Fellow, Nelson Labs



Susan has over 45 years of quality-assurance experience in the pharmaceutical industry. She has earned several awards from the Parenteral Drug Association (PDA), including Distinguished Author Award, Distinguished Service Award, and Gordon Personeus Award. Serving as a volunteer in a number of capacities, she has served on the PDA Board of Directors from 2011 to 2013 and from 2016 to 2019 and was the Chair of the board of directors from 2022 to 2024. She has served on numerous planning committees, including the PDA/FDA Joint Regulatory Conference Planning Committee since 2002. She co-hosts a monthly podcast called Ask the Expert for Pharmaceutical Technology and BioPharm International and also serves on both magazines' editorial advisory boards. She chaired the PDA's ANSI standard on quality culture, which was released in March 2025.

David Walter, B.S., Chemical Engineering
Director of Engineering, Mark Cuban's Cost Plus Drugs



As a Director of Engineering, David has spearheaded small to large-scale projects across the globe, ensuring computerized manufacturing systems meet the highest standards of safety, compliance, and efficiency. David's comprehensive technical expertise spans the entire operational continuum, from early-stage design and system configuration to hands-on installation, stringent qualification, and continuous life cycle optimization. A recognized leader in the automation space, David continues to improve on integrating engineering solutions into tightly regulated environments.

Meghan Murphy Senior Advisor, Office of Compounding Quality and Compliance, FDA

Meghan Murphy is currently a Senior Advisor in the Office of Compounding Quality and Compliance. She is the Director for Research, Strategy, and Engagement for the Compounding Quality Center of Excellence (COE). She leads and is responsible for day to day operations of the research and analysis, annual conference, strategic planning, and outreach efforts for the COE. She previously served as the Acting Associate Director for Risk Science, Intelligence, and Prioritization for the Office of Unapproved Drugs and Labeling Compliance, Center for Drug Evaluation and Research, in the U.S. Food and Drug Administration. Prior to that, Ms. Murphy was a Pharmacologist in the same organization and worked on addressing scientific and regulatory issues concerning marketed unapproved drugs and drugs compounded by pharmacists. She began her career at FDA as a member of the Department of Health and Human Services Emerging Leaders Program. Ms. Murphy obtained a Ph.D. in Pharmacology and an M.A. in Organic Chemistry from the University of North Carolina at Chapel Hill, and a B.S. in Biochemistry from the University of Maryland, Baltimore County.

Moderator

Susan C. Winckler, RPh, Esq.
CEO, Reagan-Udall Foundation for the FDA



Susan C. Winckler, RPh, Esq., is CEO of the Reagan-Udall Foundation for the Food and Drug Administration. Prior to accepting the Foundation post, Ms. Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, and other stakeholders with a neutral forum to address domestic and global issues. As Chief of Staff for the FDA (2007-2009), Winckler managed the Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges, and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her law degree magna cum laude from Georgetown University Law Center. She is an APhA Fellow, served as an elected member of the United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025) and Chair of that Board from 2019 to mid-2025. In 2023, she received the Distinguished Alumni Award of the Food and Drug Administration Alumni Association and, separately, was awarded the Osterhaus Medal for Lifetime Achievement by the Univ. of Iowa College of Pharmacy.